S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
Log in
NASDAQ:EYE

National Vision Competitors

$47.80
-1.63 (-3.30 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$47.36
Now: $47.80
$49.75
50-Day Range
$45.05
MA: $49.08
$51.94
52-Week Range
$11.70
Now: $47.80
$52.61
Volume646,403 shs
Average Volume632,480 shs
Market Capitalization$3.87 billion
P/E Ratio1,195.30
Dividend YieldN/A
Beta1.77

Competitors

National Vision (NASDAQ:EYE) Vs. ELAN, STE, ABMD, TECH, CRL, and BMRN

Should you be buying EYE stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to National Vision, including Elanco Animal Health (ELAN), STERIS (STE), Abiomed (ABMD), Bio-Techne (TECH), Charles River Laboratories International (CRL), and BioMarin Pharmaceutical (BMRN).

Elanco Animal Health (NYSE:ELAN) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends.

Volatility & Risk

Elanco Animal Health has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Elanco Animal Health and National Vision's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Elanco Animal Health-8.45%3.43%2.04%
National Vision0.32%4.97%1.84%

Institutional & Insider Ownership

86.8% of Elanco Animal Health shares are held by institutional investors. 0.1% of Elanco Animal Health shares are held by insiders. Comparatively, 2.6% of National Vision shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Elanco Animal Health and National Vision's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$3.07 billion4.97$67.90 million$1.0630.51
National Vision$1.72 billion2.25$32.80 million$0.7861.28

Elanco Animal Health has higher revenue and earnings than National Vision. Elanco Animal Health is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Elanco Animal Health and National Vision, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Elanco Animal Health22602.40
National Vision02702.78

Elanco Animal Health presently has a consensus target price of $30.50, indicating a potential downside of 5.69%. National Vision has a consensus target price of $43.25, indicating a potential downside of 9.52%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than National Vision.

National Vision (NASDAQ:EYE) and STERIS (NYSE:STE) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares National Vision and STERIS's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
National Vision0.32%4.97%1.84%
STERIS13.97%14.44%9.32%

Valuation & Earnings

This table compares National Vision and STERIS's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$1.72 billion2.25$32.80 million$0.7861.28
STERIS$3.03 billion5.01$407.61 million$5.6431.52

STERIS has higher revenue and earnings than National Vision. STERIS is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

90.0% of STERIS shares are held by institutional investors. 2.6% of National Vision shares are held by insiders. Comparatively, 1.2% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for National Vision and STERIS, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
National Vision02702.78
STERIS02302.60

National Vision presently has a consensus target price of $43.25, indicating a potential downside of 9.52%. STERIS has a consensus target price of $213.50, indicating a potential upside of 20.10%. Given STERIS's higher probable upside, analysts clearly believe STERIS is more favorable than National Vision.

Volatility & Risk

National Vision has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, STERIS has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Summary

STERIS beats National Vision on 9 of the 14 factors compared between the two stocks.

National Vision (NASDAQ:EYE) and Abiomed (NASDAQ:ABMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares National Vision and Abiomed's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
National Vision0.32%4.97%1.84%
Abiomed25.89%15.34%13.51%

Valuation and Earnings

This table compares National Vision and Abiomed's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$1.72 billion2.25$32.80 million$0.7861.28
Abiomed$840.88 million17.50$203.01 million$4.7468.63

Abiomed has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

National Vision has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for National Vision and Abiomed, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
National Vision02702.78
Abiomed12302.33

National Vision currently has a consensus target price of $43.25, indicating a potential downside of 9.52%. Abiomed has a consensus target price of $300.00, indicating a potential downside of 7.78%. Given Abiomed's higher probable upside, analysts plainly believe Abiomed is more favorable than National Vision.

Institutional & Insider Ownership

94.0% of Abiomed shares are owned by institutional investors. 2.6% of National Vision shares are owned by insiders. Comparatively, 3.4% of Abiomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Abiomed beats National Vision on 9 of the 14 factors compared between the two stocks.

National Vision (NASDAQ:EYE) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Profitability

This table compares National Vision and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
National Vision0.32%4.97%1.84%
Bio-Techne32.69%12.20%8.09%

Risk and Volatility

National Vision has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for National Vision and Bio-Techne, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
National Vision02702.78
Bio-Techne04602.60

National Vision currently has a consensus target price of $43.25, indicating a potential downside of 9.52%. Bio-Techne has a consensus target price of $352.30, indicating a potential downside of 6.16%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than National Vision.

Valuation and Earnings

This table compares National Vision and Bio-Techne's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$1.72 billion2.25$32.80 million$0.7861.28
Bio-Techne$738.69 million19.72$229.30 million$3.8697.26

Bio-Techne has lower revenue, but higher earnings than National Vision. National Vision is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. 2.6% of National Vision shares are owned by insiders. Comparatively, 3.8% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bio-Techne beats National Vision on 9 of the 14 factors compared between the two stocks.

Charles River Laboratories International (NYSE:CRL) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Charles River Laboratories International and National Vision's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories International$2.62 billion5.46$252.02 million$6.7342.71
National Vision$1.72 billion2.25$32.80 million$0.7861.28

Charles River Laboratories International has higher revenue and earnings than National Vision. Charles River Laboratories International is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Charles River Laboratories International and National Vision's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories International10.68%22.41%7.66%
National Vision0.32%4.97%1.84%

Institutional & Insider Ownership

92.3% of Charles River Laboratories International shares are owned by institutional investors. 1.9% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 2.6% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Charles River Laboratories International has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Charles River Laboratories International and National Vision, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories International041202.75
National Vision02702.78

Charles River Laboratories International currently has a consensus price target of $241.5625, indicating a potential downside of 15.97%. National Vision has a consensus price target of $43.25, indicating a potential downside of 9.52%. Given National Vision's stronger consensus rating and higher probable upside, analysts clearly believe National Vision is more favorable than Charles River Laboratories International.

Summary

Charles River Laboratories International beats National Vision on 9 of the 14 factors compared between the two stocks.

BioMarin Pharmaceutical (NASDAQ:BMRN) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares BioMarin Pharmaceutical and National Vision's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioMarin Pharmaceutical$1.70 billion8.30$-23,850,000.00$0.071,113.00
National Vision$1.72 billion2.25$32.80 million$0.7861.28

National Vision has higher revenue and earnings than BioMarin Pharmaceutical. National Vision is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioMarin Pharmaceutical and National Vision's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioMarin Pharmaceutical45.74%4.34%2.84%
National Vision0.32%4.97%1.84%

Institutional and Insider Ownership

97.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 2.2% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 2.6% of National Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

BioMarin Pharmaceutical has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, National Vision has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for BioMarin Pharmaceutical and National Vision, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioMarin Pharmaceutical081102.58
National Vision02702.78

BioMarin Pharmaceutical presently has a consensus price target of $117.3636, indicating a potential upside of 50.64%. National Vision has a consensus price target of $43.25, indicating a potential downside of 9.52%. Given BioMarin Pharmaceutical's higher probable upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than National Vision.

Summary

National Vision beats BioMarin Pharmaceutical on 8 of the 14 factors compared between the two stocks.


National Vision Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$32.34-4.1%$15.26 billion$3.07 billion-56.74Analyst Revision
STERIS logo
STE
STERIS
2.3$177.77-0.0%$15.17 billion$3.03 billion36.06
Abiomed logo
ABMD
Abiomed
1.5$325.31-0.3%$14.71 billion$840.88 million71.50
Bio-Techne logo
TECH
Bio-Techne
1.8$375.44-0.8%$14.57 billion$738.69 million60.07Analyst Upgrade
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$287.46-0.7%$14.31 billion$2.62 billion47.91
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.91-1.6%$14.14 billion$1.70 billion17.83Earnings Announcement
Analyst Report
Masimo logo
MASI
Masimo
1.4$251.31-1.9%$13.89 billion$937.84 million65.28
Canopy Growth logo
CGC
Canopy Growth
0.6$35.25-1.5%$13.25 billion$297.34 million-10.55Decrease in Short Interest
Oak Street Health logo
OSH
Oak Street Health
1.9$54.58-4.8%$13.14 billionN/A0.00Upcoming Earnings
Analyst Report
Novavax logo
NVAX
Novavax
1.2$205.99-16.7%$13.11 billion$18.66 million-39.46Earnings Announcement
Insider Selling
Gap Up
Zai Lab logo
ZLAB
Zai Lab
1.2$148.01-9.5%$13.03 billion$12.98 million-48.85Gap Up
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$59.27-0.7%$12.95 billion$4.03 billion-257.70Earnings Announcement
Dividend Announcement
Analyst Report
News Coverage
Molina Healthcare logo
MOH
Molina Healthcare
1.5$222.86-0.3%$12.93 billion$16.83 billion16.71
PPD logo
PPD
PPD
1.7$35.99-1.3%$12.58 billion$4.03 billion239.93Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.73-1.8%$11.72 billion$16.89 billion-2.92
Repligen logo
RGEN
Repligen
1.5$212.65-4.3%$11.65 billion$270.24 million259.33Analyst Revision
QIAGEN logo
QGEN
QIAGEN
1.7$50.45-0.2%$11.49 billion$1.53 billion62.28
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$32.28-1.6%$11.46 billion$8.60 billion-5.92Analyst Report
Analyst Revision
DaVita logo
DVA
DaVita
2.0$103.52-0.6%$11.33 billion$11.39 billion15.52
Grifols logo
GRFS
Grifols
1.2$16.16-2.0%$11.11 billion$5.71 billion14.43Analyst Report
Universal Health Services logo
UHS
Universal Health Services
1.5$129.35-1.1%$10.99 billion$11.38 billion12.68Earnings Announcement
Dividend Announcement
Analyst Report
Increase in Short Interest
News Coverage
Penumbra logo
PEN
Penumbra
1.5$283.15-2.9%$10.32 billion$547.41 million-1,048.70Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.4$202.24-0.7%$10.17 billion$3.34 million-26.26Earnings Announcement
Analyst Report
Analyst Revision
ABCL
AbCellera Biologics
1.7$38.00-4.4%$10.09 billionN/A0.00Decrease in Short Interest
Natera logo
NTRA
Natera
1.5$118.02-4.6%$10.08 billion$302.33 million-49.59Earnings Announcement
Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$60.44-0.0%$10.05 billion$2.32 billion49.95
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$66.17-8.7%$9.86 billion$40.56 million-19.40Earnings Announcement
Analyst Revision
Gap Up
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.5$129.77-0.4%$9.79 billion$289.59 million-39.81Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$101.42-7.9%$9.53 billion$788.10 million109.05Gap Up
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$139.93-1.8%$9.37 billion$103.71 million-31.87Analyst Report
Gap Up
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$165.75-1.8%$9.34 billion$2.16 billion52.29Analyst Report
Increase in Short Interest
Analyst Revision
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.5$142.81-1.1%$9.22 billion$3.07 billion41.76Earnings Announcement
ICON Public logo
ICLR
ICON Public
2.1$171.87-0.7%$9.22 billion$2.81 billion28.65Analyst Upgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
Gap Down
Fate Therapeutics logo
FATE
Fate Therapeutics
1.6$95.91-0.7%$8.99 billion$10.68 million-52.12Earnings Announcement
Analyst Revision
Henry Schein logo
HSIC
Henry Schein
1.7$62.92-2.6%$8.96 billion$9.99 billion15.50
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$80.63-3.9%$8.37 billion$87.99 million-95.99
Amedisys logo
AMED
Amedisys
1.2$252.53-1.0%$8.30 billion$1.96 billion50.61Analyst Report
Insider Selling
Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$155.13-0.8%$8.29 billion$14.98 million-18.90
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.4$135.85-3.2%$8.19 billion$73.99 million-52.45Earnings Announcement
Analyst Report
Analyst Revision
Encompass Health logo
EHC
Encompass Health
2.3$80.40-0.6%$7.99 billion$4.61 billion30.11Dividend Announcement
News Coverage
Syneos Health logo
SYNH
Syneos Health
1.6$75.50-1.1%$7.88 billion$4.68 billion41.48Analyst Report
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$55.30-2.3%$7.79 billion$1.12 billion115.21Earnings Announcement
Analyst Upgrade
Analyst Revision
SGFY
Signify Health
0.3$34.48-5.0%$7.64 billionN/A0.00
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.1$62.92-2.8%$7.55 billion$26.68 million-28.47Earnings Announcement
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$46.94-5.6%$7.51 billion$339.08 million-27.29Analyst Report
Analyst Revision
Invitae logo
NVTA
Invitae
1.2$42.01-4.1%$7.42 billion$216.82 million-10.80
United Therapeutics logo
UTHR
United Therapeutics
1.7$166.59-2.8%$7.42 billion$1.45 billion15.76Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.3$106.73-6.0%$7.42 billion$85.54 million0.00Upcoming Earnings
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.4$53.11-9.0%$7.39 billion$85.07 million-55.91Insider Selling
High Trading Volume
Gap Up
Sotera Health logo
SHC
Sotera Health
2.1$26.56-3.9%$7.37 billionN/A0.00Upcoming Earnings
Analyst Report
News Coverage
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.